SCHEMBL202535

SCHEMBL202535

CC(C)(C)OC(=O)N1CCn2c1nc1cnc3cccnc3c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.41
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HSD17B10 Q99714 1/20 0.40
HCRTR1 O43613 1/20 0.39
POLB P06746 2/20 0.39
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
GBA1 P04062 1/20 0.36
GPR119 Q8TDV5 3/20 0.35
KDM4E B2RXH2 2/20 0.35
MAP4K4 O95819 1/20 0.35
CKS1B P61024 1/20 0.34
SKP1 P63208 1/20 0.34
SKP2 Q13309 1/20 0.34
DTYMK P23919 1/20 0.34
PDE10A Q9Y233 2/20 0.34
SCN5A Q14524 1/20 0.34
SCN9A Q15858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL202425 0.83 MAP4K4 (0.38) KMT2AMAPTSMN1; SMN2HSD17B10HCRTR1
SCHEMBL205088 0.71 BACE1 (0.34) MAPTPOLBCKS1BSKP1SKP2
SCHEMBL1140919 0.69 POLB (0.39) POLBGBA1GPR119MAP4K4CKS1B
SCHEMBL4302702 0.69 KDM4E (0.39) KMT2AMAPTPOLBKDM4ESCN9A
SCHEMBL832462 0.68 KMT2A (0.48) KMT2AMAPTSMN1; SMN2CYP1A2CYP2C9
SCHEMBL839606 0.68 KMT2A (0.48) KMT2AMAPTSMN1; SMN2CYP1A2CYP2C9
SCHEMBL202690 0.67 PDE10A (0.36) KMT2AGBA1KDM4EMAP4K4CKS1B
SCHEMBL22075037 0.67 UCHL1 (0.37) MAPTSMN1; SMN2POLBGPR119CKS1B
SCHEMBL1231827 0.66 GBA1 (0.44) MAPTPOLBGBA1CKS1BSKP1
SCHEMBL4305882 0.65 TLR7 (0.38) KMT2APOLBKDM4ESCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088788-B2 Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS PFIZER INC. 2009-09-03 US disclosed
WO-2007106852-A2 SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS IL2, IFNG, IL4 KMT2A 3293/4885MAPT 4635/4885SMN1; SMN2 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.